Andrew D. Campbell

Andrew D. Campbell has an extensive work experience in the pharmaceutical and biotechnology industry. Andrew D. has held various leadership positions throughout their career. Currently, they serve as a Strategic Advisory Board Member for PAR Clinical. Prior to that, they worked as the Vice President, Global Head of Program Management at APRINOIA Therapeutics, where they led multiple programs in the development of diagnostics and therapeutics for neurodegenerative disorders. Additionally, they have served as a Program Executive in the Psychiatry and Movement Disorders Portfolio at Praxis Precision Medicines, Inc., and as a Program Team Lead in Gene Therapy at Ultragenyx Pharmaceutical Inc. Andrew D. has also held positions such as Vice President, Program Team Leader at Sage Therapeutics, Executive Director, Medical Operations at Intarcia Therapeutics, Inc., and Sr. Director Medical Affairs Operations, NA at Sobi. Earlier in their career, they worked at Biogen as a Sr. Director Corporate Strategy and Senior Director, Global Medical Operations. Andrew D. also served as the Sr. Director Medical and Clinical Affairs at Dyax and held various roles at Sunovion Pharmaceuticals Inc. as Sr. Program Director, CNS Therapeutic Assessment Team Leader, and Director/Sr. Director CNS Medical Liaisons. Throughout their career, Andrew has demonstrated strong leadership, strategic planning, and collaboration skills.

Andrew D. Campbell earned a Bachelor of Science (BS) degree in Biology from the University of Maine, where they studied from 1983 to 1987. Subsequently, they pursued a Ph.D. in Pharmaceutical Sciences at the University of Colorado Boulder from 1987 to 1992.